209 related articles for article (PubMed ID: 16503818)
1. Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality.
Pfützner A; Forst T
Expert Opin Pharmacother; 2006 Mar; 7(4):463-76. PubMed ID: 16503818
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone: a review of its use in type 2 diabetes mellitus.
Waugh J; Keating GM; Plosker GL; Easthope S; Robinson DM
Drugs; 2006; 66(1):85-109. PubMed ID: 16398569
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects.
Pfützner A; Weber MM; Forst T
Expert Opin Pharmacother; 2007 Aug; 8(12):1985-98. PubMed ID: 17696799
[TBL] [Abstract][Full Text] [Related]
4. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
5. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
6. [Glycemic control and cardiovascular benefit: What do we know today?].
Hanefeld M; Schönauer M; Forst T
Dtsch Med Wochenschr; 2010 Feb; 135(7):301-7. PubMed ID: 20146161
[TBL] [Abstract][Full Text] [Related]
7. [Proactive study: secondary cardiovascular prevention with pioglitazione in type 2 diabetic patients].
Scheen AJ; Lefèbvre PJ
Rev Med Liege; 2005 Nov; 60(11):896-901. PubMed ID: 16402538
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects.
Pfützner A; Schneider CA; Forst T
Expert Rev Cardiovasc Ther; 2006 Jul; 4(4):445-59. PubMed ID: 16918264
[TBL] [Abstract][Full Text] [Related]
9. Redefining the role of thiazolidinediones in the management of type 2 diabetes.
Barnett AH
Vasc Health Risk Manag; 2009; 5(1):141-51. PubMed ID: 19436665
[TBL] [Abstract][Full Text] [Related]
10. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
Stolar MW; Chilton RJ
Clin Ther; 2003; 25 Suppl B():B4-31. PubMed ID: 14553864
[TBL] [Abstract][Full Text] [Related]
11. Progress with thiazolidinediones in the management of type 2 diabetes mellitus.
Meriden T
Clin Ther; 2004 Feb; 26(2):177-90. PubMed ID: 15038941
[TBL] [Abstract][Full Text] [Related]
12. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients.
Charbonnel B; Dormandy J; Erdmann E; Massi-Benedetti M; Skene A;
Diabetes Care; 2004 Jul; 27(7):1647-53. PubMed ID: 15220241
[TBL] [Abstract][Full Text] [Related]
13. Organ protection in the secondary prevention of type 2 diabetes.
Schernthaner G
Drugs Today (Barc); 2006 Dec; 42 Suppl C():17-23. PubMed ID: 17245477
[TBL] [Abstract][Full Text] [Related]
14. Effect of pioglitazone on endothelial function in impaired glucose tolerance.
Quinn CE; Lockhart CJ; Hamilton PK; Loughrey CM; McVeigh GE
Diabetes Obes Metab; 2010 Aug; 12(8):709-15. PubMed ID: 20590748
[TBL] [Abstract][Full Text] [Related]
15. [Glucose-independent impact of the glitazones on the cardiovascular outcome].
Hanefeld M
MMW Fortschr Med; 2005 Jan; 147(1-2):37-9. PubMed ID: 15704569
[TBL] [Abstract][Full Text] [Related]
16. PROactive: time for a critical appraisal.
Betteridge DJ; DeFronzo RA; Chilton RJ
Eur Heart J; 2008 Apr; 29(8):969-83. PubMed ID: 18375395
[TBL] [Abstract][Full Text] [Related]
17. Association between insulin resistance and endothelial dysfunction in type 2 diabetes and the effects of pioglitazone.
Suzuki M; Takamisawa I; Yoshimasa Y; Harano Y
Diabetes Res Clin Pract; 2007 Apr; 76(1):12-7. PubMed ID: 17007957
[TBL] [Abstract][Full Text] [Related]
18. Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis.
Clar C; Royle P; Waugh N
PLoS One; 2009 Jul; 4(7):e6112. PubMed ID: 19568428
[TBL] [Abstract][Full Text] [Related]
19. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes.
Martens FM; Visseren FL; de Koning EJ; Rabelink TJ
J Cardiovasc Pharmacol; 2005 Dec; 46(6):773-8. PubMed ID: 16306801
[TBL] [Abstract][Full Text] [Related]
20. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
Defronzo RA; Mehta RJ; Schnure JJ
Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
